Original language | English (US) |
---|---|
Pages (from-to) | 546-548.e4 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 21 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2023 |
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical Gastroenterology and Hepatology, Vol. 21, No. 2, 02.2023, p. 546-548.e4.
Research output: Contribution to journal › Short survey › peer-review
}
TY - JOUR
T1 - Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
AU - PRIORITIZE Study Team
AU - Lok, Anna S.
AU - Moon, Juhi
AU - Sherman, Kenneth E.
AU - Khalili, Mandana
AU - Fishbein, Dawn
AU - Reddy, K. Rajender
AU - Morelli, Giuseppe
AU - Peter, Joy
AU - Nelson, David R.
AU - Pearlman, Brian
AU - Michael, Larry
AU - Fried, Michael W.
AU - Segal, Jodi B.
AU - Sulkowski, Mark S.
N1 - Funding Information: Funding Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (HPC-1503-27891). Free drug was provided by AbbVie Pharmaceuticals, Abbott Park, IL. Free drug was provided by Merck and Co, Whitehouse Station, NJ. Kroger Specialty Pharmacy provided support in kind pharmacy services for Merck and AbbVie product. The views and statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Drs. Khalili (K24AA022523) and Sulkowski (K24DA034621) were also partially supported by the National Institutes of Health. Funding Information: Conflicts of interest These authors disclose the following: Anna S. Lok reports grant funding from Bristol-Myers Squibb; and serves on the advisory board for Gilead, and HCV-TARGET. Kenneth E Sherman reports grants/contracts (paid to institution) by AbbVie, Gilead, Intercept, and Zydus; serves on the advisory board and performs consulting for Gilead and Theratechnologies; and is on the DSMB/adjudication committees for Inovio, MedPace, and Horizon. Mandana Khalili reports grant funding from Gilead Sciences Inc and Intercept Pharmaceuticals; and is a consultant for Gilead Sciences Inc. Dawn Fishbein reports grants from Gilead Focus partnership (past) and Gilead Sciences Inc; owns stock in AbbVie and Merck over the years <$10,000 has been held in discretionary account without any personal authority to buy or sell any stock position; however, her father and brother are the portfolio managers; and served on the Gilead Advisory Board for 2020. K. Rajender Reddy reports grants from Gilead, Intercept, Exact Sciences, HCC-TARGET, HCV-TARGET, NASH-TARGET, Mallinckrodt, Bristol-Myers Squibb, Sequana, and Grifols; reports personal fees from Spark Therapeutics, Novo Nordisk, and Mallinckrodt; and is on the DSMB for Novartis. Brian Pearlman reports grants from AbbVie, Merck, and Gilead; is a consultant for AbbVie, Merck, and Gilead; has done sponsored lectures and received honoraria for AbbVie, Merck, and Gilead. Michael W. Fried reports grants from AbbVie, Bristol-Myers Squibb, Merck, and Gilead; reports personal fees from AbbVie, Bristol-Myers Squibb, Merck, and Roche; reports personal fees and other from TARGET PharmaSolutions, outside the submitted work; reports research grants from the National Institutes of Health; and is a stockholder of TARGET PharmaSolutions. Joy Peter reports that her domestic partner is an AbbVie Stockholder. Jodi B. Segal reports grant funding from the National Institutes of Health, National Institute of Health Care Management, Arnold Foundation, and the United States Food and Drug Administration; is an employee at Johns Hopkins University; and is a contractor for the American College of Physicians. Mark S. Sulkowski reports funds paid to Johns Hopkins University by AbbVie, Assembly Biosciences, Janssen; and is a consultant for AbbVie, Gilead, Antios, GSK, and Assembly Biosciences. David R. Nelson reports grants from AbbVie, Gilead and Merck during the conduct of the study; and is a stockholder of TARGET PharmaSolutions. Funding Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (HPC-1503-27891). Free drug was provided by AbbVie Pharmaceuticals, Abbott Park, IL. Free drug was provided by Merck and Co, Whitehouse Station, NJ. Kroger Specialty Pharmacy provided support in kind pharmacy services for Merck and AbbVie product. The views and statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. Drs. Khalili (K24AA022523) and Sulkowski (K24DA034621) were also partially supported by the National Institutes of Health.
PY - 2023/2
Y1 - 2023/2
UR - http://www.scopus.com/inward/record.url?scp=85127318832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127318832&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2022.01.059
DO - 10.1016/j.cgh.2022.01.059
M3 - Short survey
C2 - 35182741
AN - SCOPUS:85127318832
SN - 1542-3565
VL - 21
SP - 546-548.e4
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 2
ER -